Lenny Dragone

Company: Abata Therapeutics

Job title: Chief Medical Officer

Seminars:

Resetting the Immune System with TCR-engineered Autologous Tregs for Tissue Specific Tolerance Induction 5:15 pm

Testing the therapeutic potential of TCR-engineered autoantigen specific Tregs to reset immune tolerance to treat progressive-MS or T1D Defining drivers of tissue residency and durability of TCR-engineered Tregs Measuring long lasting tolerance induction; considerations of clinical trial lengthRead more

day: Conference Day One

Panel & Audience Discussion: Supercharging Antigen-Specific Approaches to Autoimmune Disease Patients: Evaluating the Next Steps to Move Forward as a Field 3:45 pm

Selecting antigens – what makes a ‘good’ antigen? Assessing preclinical models – what should we move towards for regulatory buy-in? Creating a biomarker toolbox – what biomarkers could be a tolerance endpoint? Honing clinical study design – what are key considerations for tolerance?Read more

day: Conference Day Two